Baidu
map

卒中患者吞咽障碍和营养管理专家共识

2014-02-27 佚名 健康报

由45位国内神经内科专家编写的《卒中患者吞咽障碍和营养管理的中国专家共识(2013版)》日前颁布,这对提高临床医师对该疾病的诊治水平,规范临床医疗实践具有重要的指导意义。 《共识》主要执笔人、中华预防医学会卒中预防与控制专业委员会主任委员、首都医科大学附属北京天坛医院副院长王拥军教授介绍,2013版《共识》在对《中国卒中患者营养管理的专家共识》(2007年)修订的基

由45位国内神经内科专家编写的《卒中患者吞咽障碍和营养管理的中国专家共识(2013版)》日前颁布,这对提高临床医师对该疾病的诊治水平,规范临床医疗实践具有重要的指导意义。

《共识》主要执笔人、中华预防医学会卒中预防与控制专业委员会主任委员、首都医科大学附属北京天坛医院副院长王拥军教授介绍,2013版《共识》在对《中国卒中患者营养管理的专家共识》(2007年)修订的基础上,又吸纳了一些新近发表的循证医学证据和国际指南内容。2013版《共识》共推出意见10条,采用牛津循证医学中心临床证据水平分级和推荐级别。

《共识》指出,吞咽障碍及营养不良能显著增加卒中患者不良预后风险;卒中患者在进食或饮水前应进行吞咽障碍筛查;对确认存在吞咽障碍的患者应给予促进吞咽功能恢复的治疗;针灸、吞咽康复、饮食改进、姿势改变等可改善吞咽功能;对吞咽障碍的卒中患者不推荐早期应用PEG(经皮胃造瘘),如需长期肠内营养,可酌情考虑PEG喂养;目前尚无足够高级别证据证明卒中后7天内开始肠内营养较7天开始能改善临床结局。

《共识》指出,卒中患者入院后可进行营养筛查,必要时每周可重复筛查,监测是否具有营养风险;对筛查结果异常的患者,应请专业人员进行评估;对营养筛查结果提示存在营养风险的患者,应请营养师给予进一步的营养评估,提出干预措施;对包括重症在内的卒中患者,应在入院24小时~48小时开始肠内营养。

《共识》指出,规范的肠内营养操作可减少吸入性肺炎、腹泻、呕吐等并发症,地中海饮食可预防卒中的发生,应根据患者的病情,给予个体化的能量和营养配方,选用富含单不饱和脂肪酸和膳食纤维的配方。

《共识》还对糖尿病患者如何选用肠内营养制剂,需要限制液体入量的患者及便秘患者选用何种膳食配方等给出了具体的指导。

下载:

卒中患者吞咽障碍和营养管理的中国专家共识(2013版)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1844427, encodeId=8732184442e98, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon Jan 26 02:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720015, encodeId=74b91e2001562, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed May 28 16:17:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8079, encodeId=392480e970, content=有下载的了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Mar 05 10:18:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509802, encodeId=1d6915098024f, content=<a href='/topic/show?id=9bbc8816381' target=_blank style='color:#2F92EE;'>#营养管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88163, encryptionId=9bbc8816381, topicName=营养管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f10138976, createdName=zhangbaojun, createdTime=Sat Mar 01 00:17:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7887, encodeId=2c02e887f7, content=提供链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:03:00 CST 2014, time=2014-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1844427, encodeId=8732184442e98, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon Jan 26 02:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720015, encodeId=74b91e2001562, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed May 28 16:17:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8079, encodeId=392480e970, content=有下载的了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Mar 05 10:18:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509802, encodeId=1d6915098024f, content=<a href='/topic/show?id=9bbc8816381' target=_blank style='color:#2F92EE;'>#营养管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88163, encryptionId=9bbc8816381, topicName=营养管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f10138976, createdName=zhangbaojun, createdTime=Sat Mar 01 00:17:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7887, encodeId=2c02e887f7, content=提供链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:03:00 CST 2014, time=2014-02-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1844427, encodeId=8732184442e98, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon Jan 26 02:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720015, encodeId=74b91e2001562, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed May 28 16:17:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8079, encodeId=392480e970, content=有下载的了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Mar 05 10:18:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509802, encodeId=1d6915098024f, content=<a href='/topic/show?id=9bbc8816381' target=_blank style='color:#2F92EE;'>#营养管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88163, encryptionId=9bbc8816381, topicName=营养管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f10138976, createdName=zhangbaojun, createdTime=Sat Mar 01 00:17:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7887, encodeId=2c02e887f7, content=提供链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:03:00 CST 2014, time=2014-02-27, status=1, ipAttribution=)]
    2014-03-05 gongzuozhong

    有下载的了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1844427, encodeId=8732184442e98, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon Jan 26 02:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720015, encodeId=74b91e2001562, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed May 28 16:17:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8079, encodeId=392480e970, content=有下载的了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Mar 05 10:18:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509802, encodeId=1d6915098024f, content=<a href='/topic/show?id=9bbc8816381' target=_blank style='color:#2F92EE;'>#营养管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88163, encryptionId=9bbc8816381, topicName=营养管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f10138976, createdName=zhangbaojun, createdTime=Sat Mar 01 00:17:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7887, encodeId=2c02e887f7, content=提供链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:03:00 CST 2014, time=2014-02-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1844427, encodeId=8732184442e98, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon Jan 26 02:17:00 CST 2015, time=2015-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720015, encodeId=74b91e2001562, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Wed May 28 16:17:00 CST 2014, time=2014-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=8079, encodeId=392480e970, content=有下载的了, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150602/IMG556D2C119C3EC8067.jpg, createdBy=e2ea89702, createdName=gongzuozhong, createdTime=Wed Mar 05 10:18:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509802, encodeId=1d6915098024f, content=<a href='/topic/show?id=9bbc8816381' target=_blank style='color:#2F92EE;'>#营养管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88163, encryptionId=9bbc8816381, topicName=营养管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b9f10138976, createdName=zhangbaojun, createdTime=Sat Mar 01 00:17:00 CST 2014, time=2014-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=7887, encodeId=2c02e887f7, content=提供链接?, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:03:00 CST 2014, time=2014-02-27, status=1, ipAttribution=)]
    2014-02-27 匿名用户

    提供链接?

    0

相关资讯

Eur Heart J:房颤患者应用华法林或需过渡策略

一项来自加拿大的回顾性病例对照研究显示,房颤患者在接受华法林抗凝治疗后,第一个月内缺血性卒中风险反而升高,但此后卒中风险逐渐降低至基线水平以下。(Eur Heart J. 2013年12与18日在线版)据研究者介绍,在着名的ROCKET AF和ARISTOTLE研究中,接受新型口服抗凝剂利伐沙班或阿哌沙班治疗的房颤患者在过渡至华法林治疗后,卒中风险也升高。主要研究者Laurent Azoulay认

Stroke:我国卒中领域SMART项目是否可行?

近日,北京协和医院崔丽英教授等公布的SMART (卒中管理与临床研究培训)项目最新结果表明,SMART项目在我国缺血性卒中二级预防中可行,但该项目在提高患者的治疗依从性和改善1年临床结局等方面的作用有限。研究者指出,我国人群中缺血性卒中发生率较高,而患者对二级预防措施的依从性较差。SMART项目可提高我国缺血性卒中患者对他汀治疗的依从性,该研究为调整卒中管理方案提供了有用的信息,从而为进一步改善卒

Front Biosci:常用漱口水或致心脏病和卒中

据外媒报道,英国科学家近日发表研究称,常用漱口水对人体健康是“灾难”,有可能增加心脏病和中风的危险。 英国伦敦大学皇后玛丽学院教授Ahluwalia A近日在《前沿生物学与医学》杂志发表了这份研究结果。研究称漱口水杀死了口中“有益”的细菌,而这种细菌可以帮助血管软化,使用漱口水可能让血压升高。 阿卢瓦利亚表示,将所有的细菌杀死是一场灾难。一旦血压有所升高,将提高

ISC 2014:植入式监测仪可发现不明原因卒中患者的心房颤动

2014国际卒中大会(ISC)上,Richard A. Bernstein博士(美国西北大学)报告的CRYSTAL-AF研究结果显示,对于发生不明原因卒中的患者,使用植入式心脏监测仪的心房颤动(房颤)检出率显著高于标准监测。研究者表示,房颤是卒中最重要的危险因素之一,可通过抗凝治疗预防,监测仪能显著降低卒中复发率。研究入选441例不明原因卒中患者,所有患者在卒中90天内接受至少24小时的标准心脏监

Stroke:危险因素叠加致卒中复发风险倍增(CICAS研究)

目前我国每年新发脑卒中病例约250万人,约175万人为缺血性脑卒中患者,其中近半数缺血性脑卒中患者合并颅内动脉粥样硬化性狭窄,约为81万人。这一结论来自于国家“十一五”课题中国颅内动脉粥样硬化性狭窄研究。该研究结果日前已在国际知名学术期刊《卒中》上发表。 此项研究是亚洲第一个关于颅内动脉粥样硬化性狭窄分布及预后的大型、前瞻性、多中心队列研究,共纳入22家医疗机构、2

六成脑卒中患者面临高复发风险

12月27日,2013年脑卒中二级预防规范化管理临床实践项目工作总结暨经验交流会在京举行。中华医学会神经病学分会副主任委员、北京协和医院神经科主任崔丽英透露,该项目对全国6万多名卒中患者的初步分析显示,近六成脑卒中患者面临卒中高复发风险,由此提示包括生活方式干预、危险因素控制、药物治疗在内的脑卒中二级预防管理非常重要。 我国临床资料表明门诊脑卒中患者约40%是二次以

Baidu
map
Baidu
map
Baidu
map